linjc16/ctgov huggingface dataset:
Rifaximin for Functional Dyspepsia

Study Overview
=================
Brief Summary
-----------------
Functional dyspepsia is a very common medical condition, which occurs in up to 30% of people in the community. However, results of current pharmacological treatment on functional dyspepsia are unsatisfactory. Rifaximin is a minimally absorbed antibiotic that has been used in treatment of non-constipated irritable bowel syndrome (IBS). In particular, bloating and abdominal pain was improved by rifaximin treatment in this group of IBS patients. Whilst there is considerable overlap in symptoms of functional dyspepsia and IBS, the investigators test whether rifaximin is also effective in curing post-prandial distress symptoms related to dyspepsia.

Detailed Description
-----------------
The aim of this study is to test the effects of rifaximin, a minimally absorbed antibiotics, on symptoms of patients with functional dyspepsia.

Official Title
-----------------
Use of Rifaximin in Patients With Functional Dyspepsia: A Randomized Controlled Trial

Conditions
-----------------
Functional Dyspepsia

Intervention / Treatment
-----------------
* Drug: Rifaximin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-ulcer dyspeptic patients who fulfill post-prandial distress syndrome according to the Rome III Criteria Active dyspeptic symptom Normal upper endoscopy Urea Breath Test -ve or Rapid urease test -ve Not typical gastroesophageal reflux or biliary colic symptoms, but presence of infrequent acid reflux is allowed Exclusion Criteria: No active dyspeptic symptom Allergic to rifaximin Recent antibiotics use in the past 8 wk Recent PPI or H2RA in past 4 wk On anti-coagulants, anti-convulsant or oral contraceptives On NSAIDs, aspirin or Clopidogrel Pregnancy or breast feeding Previous gastric surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Rifaximin<br> | Drug: Rifaximin<br>* Rifaximin 400mg tid for 2 wk<br>* Other names: Normix;|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Placebo for 2 week<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adequate relief of dyspeptic symptoms at end of treatment | global symptom improvement | end of treatment (week 2) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Individual dyspeptic symptom scores | Hong Kong Dyspeptic Index | week 2, 4 and 8 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Post-prandial distress syndrome
Physical Performance Measures for Manual Wheelchair Users

Study Overview
=================
Brief Summary
-----------------
The project is intended to modify the Functional Independence Measure (FIM) for manual wheelchair users. It will determine if the new measure is a better measure of community independence for manual wheelchair users than the FIM. During the Phase 1 of the study it will then use this new measure to determine whether a home exercise program increases functional independence in wheelchair users. In Phases II and III of the study 120 manual wheelchair users will participate to test and validate the new measure and to test the effectiveness of therapeutic exercise. Subjects will range in age from 20 to 79 yrs. and have a variety of disabilities.

Official Title
-----------------
Physical Performance Measures for Manual Wheelchair Users

Conditions
-----------------
Spinal Cord Injury

Intervention / Treatment
-----------------
* Procedure: Performance Measure


Participation Criteria
=================
Eligibility Criteria
-----------------
Wheelchair users

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Performance Measure|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
wheelchair, biomechanics, aging, functional outcome, disability
The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment

Study Overview
=================
Brief Summary
-----------------
Recent studies have described the role of melatonin as a sleep regulator and as an anti- oxidative neuroprotective agent in improving sleep quality and delaying cognitive decline in Alzheimer's disease (AD). In accordance with this data, our hypothesis is that melatonin will delay the cognitive decline in Mild Cognitive Impairment (MCI) patients and reduce the conversion rate from MCI to AD.

Official Title
-----------------
The Effect of Melatonin on Memory and Other Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment (MCI): A Placebo- Controlled Study.

Conditions
-----------------
Mild Cognitive Impairment (MCI)

Intervention / Treatment
-----------------
* Drug: melatonin
* Drug: placebo like melatonin tablets


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: MCI assessment according to the Peterson et al. (2001) criteria. Age 55-90 years, inclusive. Study informant available. Mini Mental Status Examination ; MMSE 24-30. Adequate vision and hearing for neuropsychological testing. Normal vitamin B12 level and thyroid function. Exclusion Criteria: Significant cerebral vascular disease (Modified Hachinski scale > 4). Depression (Hamilton Depression Rating Scale > 12). Central nervous system infarct, infection or focal lesions of clinical significance on CT or MRI scans. Medical diseases or psychiatric disorders that could interfere with study participation. Pregnant, lactating or childbearing potential. Taking vitamin supplements or other supplements. Restrictions on concomitant medication usage, including those with significant cholinergic or anti-cholinergic effects or potential adverse effects on cognition.

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>melatonin 5 mg, daily dose for 6 months | Drug: melatonin<br>* 5 mg, oral, daily dose for 6 months<br>|
| Placebo Comparator: B<br> | Drug: placebo like melatonin tablets<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| a delay in cognitive decline as measured by memory tests |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduced MCI conversion rate to AD per year |  | Two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Memory, Mild Cognitive Impairment, Melatonin, Antioxidant, Alzheimer
Multimodal Analgesia for the Reduction of Postoperative Opioid Consumption

Study Overview
=================
Brief Summary
-----------------
The investigators are performing this research study to investigate the efficacy of local infiltration of the surgical wound combining dexmedetomidine, ropivacaine, and ketorolac (treatment group) versus the current standard of care (historical control group), for post-operative pain management.

Detailed Description
-----------------
During this research study, patients recommended for a rectus sheath block during surgery will receive a novel combination of non-opioid drugs. Data from the treatment group will be compared to surgical outcomes of a historically matched control group to investigate the ability of this drug combination to reduce post-operative pain and post-operative opioid consumption.

Official Title
-----------------
Multimodal Analgesia for the Reduction of Postoperative Opioid Consumption

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: Multimodal analgesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age greater than 18 years American Society of Anesthesiologist Physical Status Classification 1-3 Undergoing surgery requiring a rectus sheath block Exclusion Criteria: American Society of Anesthesiologist Physical Status Classification of 4 or beyond history of opiate of illicit substance abuse, chronic pain, or neurological dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Multimodal Analgesia<br> | Drug: Multimodal analgesia<br>* Subjects will be given a rectus sheath block containing dexmedetomidine, ropivacaine, and ketorolac<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in post-operative opioid consumption | Decreased post-operative opioid consumption associated with use of multimodal analgesia | 48 hours | 
| Change in post-operative pain scores | Decreased post-operative pain scores associated with use of multimodal analgesia | 48 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
multimodal, dexmedetomidine, ropivacaine, ketorolac, pain management, opioid sparing, analgesia
Pharmacokinetics of Curcumin in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
This study looks to describe the pharmacokinetics of curcumin delivered as a single oral dose in healthy female volunteers. The impact of piperine and silybin on the pharmacokinetics of curcumin is also studied.

Detailed Description
-----------------
Healthy volunteers are seen on three separate visits and receive 4 gm of curcumin as a single oral dose either alone or with piperine or with silybin. Serial timed blood draws then are collected for pharmacokinetic analysis.

Official Title
-----------------
Evaluation of Naturally Occurring Inhibitors of UDP-glucuronyltransferase on the Oral Bioavailability of Curcumin in Normal Healthy Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Curcumin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteer On no medications except for birth control pills Signed informed consent Exclusion Criteria: Pregnant Comorbid disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Curcumin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Curcumin pharmacology |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Interactions between piperine and curcumin |  |  | 
| Interactions between silybin and curcumin |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Silybin, Curcumin, Piperine, Healthy volunteer, Female
Oral Bacteria on Suture Materials - Clinical Comparison of an Antibacterial-coated and a Non-coated Suture Material

Study Overview
=================
Brief Summary
-----------------
Antibacterial Triclosan-coated suture material (VICRYL PLUS®, Ethicon) and non-coated (VICRYL®) was compared for bacterial colonization after third molar extraction. Sutures were removed postoperatively and adhered bacteria were investigated.

Official Title
-----------------
Oral Bacteria on Suture Materials - Clinical Comparison of an Antibacterial-coated and a Non-coated Suture Material (VICRYL PLUS® vs. VICRYL®, Ethicon) in Intraoral Dentoalveolar Surgery

Conditions
-----------------
Bacterial Colonization

Intervention / Treatment
-----------------
* Device: Vicryl Plus
* Device: Vicryl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: planned surgical extraction of 1 to 4 wisdom teeth no inflammation and pain within the planned surgical area legal age clinically healthy patient Exclusion Criteria: allergy to Triclosan or phenols gravidity/lactation immunosuppression due to drugs or diseases severe general diseases long-term medication intake or use of other antibiotical drugs/devices

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vicryl Plus<br> | Device: Vicryl Plus<br> <br> |
| Active Comparator: Vicryl<br> | Device: Vicryl<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Checking clinical antibacterial effect of Vicryl Plus compared to conventional Vicryl in intraoral surgery, Bacteria
Effectiveness of the Walking Intervention Walkadoo: A Randomized Controlled Pilot Trial in an Employee Population

Study Overview
=================
Brief Summary
-----------------
This study evaluates the product Walkadoo to determine whether it effectively increases walking behavior in healthy adults.

Official Title
-----------------
Effectiveness of the Walking Intervention Walkadoo: A Randomized Controlled Pilot Trial in an Employee Population

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Behavioral: Walkadoo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults 18 years or older; Healthways employees based in Franklin, TN with an email account with the company; Provide informed consent and complete eligibility questionnaires Exclusion Criteria: Current or prior use of the intervention Walkadoo Presence of a chronic condition that affects walking Projected inability to access the internet for 4 consecutive days or longer during the study Non-adherence to device wear during baseline

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>Observation only, no behavioral intervention | |
| Experimental: Intervention<br>Intervention Walkadoo. | Behavioral: Walkadoo<br>* Walkadoo is a MeYou Health, LLC product.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average steps per day |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adults
Incidence and Risk of Influenza in Myasthenic Patients

Study Overview
=================
Brief Summary
-----------------
Upper respiratory infection , including influenza, may exacerbate the symptoms of myasthenia gravis (MG), which is an autoimmune disease that causes muscle weakness and, in some cases, can precipitate a myasthenic crisis In the present study, we investigated the incidence and risk factors of influenza infection on in myasthenia gravis patients.

Detailed Description
-----------------
This is a descriptive study. The data will be analyzed retrospectively . Inclusion of 416 cases of influenza in myasthenic patients treated in the intensive care unit of Garches Hospital between January 1, 2009 and December 31, 2017. Patients who meet the inclusion and non inclusion criteria and do not object to participate in the study will be collected in a database for analysis.

Official Title
-----------------
Incidence and Risk of Influenza in Myasthenic Patients Hospitalized in Intensive Care

Conditions
-----------------
Myasthenic Crisis, Upper Respiratory Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men or women over the age of 18. Myasthenic patients hospitalized in intensive care. Patients with confirmed influenza infection Exclusion Criteria: Age <18 years, Other neuromuscular diseases, Patient opposing the use of his data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of influenza in myasthenic patient in crisis | Number of influenza cases in myasthenic patients | between January 1, 2009 and December 31, 2017. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors for poor outcomes | To identify risk factors for severe influenza in myasthenic patients | between January 1, 2009 and December 31, 2017. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Influenza A virus, myasthenia gravis, neurocritical care clinical, neuromuscular disease
Effects of 2 Different Doses of Pantoprazole on Gastric pH and Recurrent Bleeding in Patients Who Bled From Peptic Ulcers

Study Overview
=================
Brief Summary
-----------------
Endoscopic treatment of bleeding peptic ulcers is effective to prevent rebleeding. Adjuvant medical treatment to increase gastric pH may further decrease rebleeding. Recent studies on potent acid suppression by proton pump inhibitors (PPI) demonstrated the efficacy in preventing rebleeding. Lau demonstrated that high dose intravenous infusion of omeprazole decreased rebleeding in peptic ulcers with stigmata of recent hemorrhage. There is little data regarding the effect of pantoprazole on bleeding peptic ulcers. Furthermore, the optimal dose of PPI is unknown. Few studies have included measurement of gastric pH in addition to clinical outcome. This study compares the effect of two doses of intravenous pantoprazole with no acid suppression in bleeding peptic ulcers after endoscopic therapy. In addition to the usual clinical endpoints, gastric pH is monitored to study the relation of pH elevation and the clinical outcome.

Conditions
-----------------
Peptic Ulcer Hemorrhage

Intervention / Treatment
-----------------
* Drug: pantoprazole infusion
* Drug: pantoprazole bolus
* Drug: no treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients presenting with upper gastrointestinal bleeding with upper endoscopy showing a bleeding peptic ulcer with major stigmata of haemorrhage and after successful endoscopic haemostasis. Exclusion Criteria: previous gastrectomy and vagotomy patient taking warfarin intake of anti-secretory drugs in the previous 48 hours

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: pantoprazole infusion|nan|
|Drug: pantoprazole bolus|nan|
|Drug: no treatment|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rebleeding rate within 30 days after endoscopic therapy |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Transfusion requirement |  |  | 
| duration of hospital stay |  |  | 
| need for operative intervention |  |  | 
| mortality rate |  |  | 
| gastric pH |  |  | 
| side effects of pantoprazole |  |  |